SGLT2 inhibitors are a class of prescription medicines that are FDA-approved for use with diet and exercise to lower blood sugar in adults with type 2 […]

Anuncio de seguridadInformación adicional para pacientesInformación adicional para profesionales de la saludResumen de datos Anuncio de seguridad El 17 de diciembre del 2012, La Administración de […]

The FDA has issued new information about this safety issue, see the FDA Drug Safety Communications issued 5/13/2014 and 11-02-2012 Safety AnnouncementAdditional Information for PatientsAdditional Information […]

FDA’s Division of Drug Information in the Center for Drug Evaluation and Research (CDER) is excited to present a series of educational webinars targeting the needs […]

[7-26-16] Today, the FDA has approved labeling changes for antibacterial drugs called fluoroquinolones, including an updated Boxed Warning, and advising that the serious side effects associated with […]

Safety Announcement [7-26-2013]   The U.S. Food and Drug Administration (FDA) is taking several actions related to Nizoral (ketoconazole) oral tablets, including limiting the drug’s use, warning […]

Safety AnnouncementAdditional Information for Consumers and CaregiversAdditional Information for Healthcare ProfessionalsData Summary References Safety Announcement [04-07-2011] The U.S. Food and Drug Administration (FDA) is warning the public […]

For 2006 Safety information, please see the FDA Archive Safety AnnouncementAdditional Information for PatientsAdditional Information for Healthcare ProfessionalsData Summary References Safety Announcement [04-07-2011] The U.S. Food and […]

We conducted a drug utilization analysis of concomitant use of benzodiazepines with buprenorphine products being used for medication-assisted treatment (MAT), using the Prescription Behavior Surveillance System’s […]